174 related articles for article (PubMed ID: 32452359)
1. [Finding mutations of interest in circulating tumor DNA helps predict immunotherapy response in lung cancer].
Guibert N; Pradines A; Favre G; Mazières J
Med Sci (Paris); 2020 May; 36(5):437-439. PubMed ID: 32452359
[No Abstract] [Full Text] [Related]
2. Circulating tumor DNA: A promising biomarker to guide postoperative treatment and surveillance of non-small cell lung cancer.
Isbell JM; Jones DR; Li BT
J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2628-2631. PubMed ID: 29615336
[No Abstract] [Full Text] [Related]
3. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumour DNA in
Cabanero M; Tsao MS
Curr Oncol; 2018 Jun; 25(Suppl 1):S38-S44. PubMed ID: 29910646
[TBL] [Abstract][Full Text] [Related]
5. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.
Scilla KA; Rolfo C
Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467
[TBL] [Abstract][Full Text] [Related]
6. Monitoring immunotherapy outcomes with circulating tumor DNA.
Goldberg SB; Patel AA
Immunotherapy; 2018 Sep; 10(12):1023-1025. PubMed ID: 30185140
[No Abstract] [Full Text] [Related]
7. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA for personalized lung cancer monitoring.
Fiala C; Diamandis EP
BMC Med; 2017 Aug; 15(1):157. PubMed ID: 28814291
[TBL] [Abstract][Full Text] [Related]
9. Next-generation sequencing of circulating tumor DNA for metastatic non-small cell lung cancer: a discussion on its implementation in the Brazilian clinical practice.
H Araujo L; Ferreira CG; Baldotto CS; Mathias C; Castro G; Coudry R
Future Oncol; 2021 Jan; 17(2):205-213. PubMed ID: 33052747
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA testing in advanced non-small cell lung cancer.
Moding EJ; Diehn M; Wakelee HA
Lung Cancer; 2018 May; 119():42-47. PubMed ID: 29656751
[TBL] [Abstract][Full Text] [Related]
11. Blood-based tumour mutational burden analysis in NSCLC.
Das M
Lancet Oncol; 2018 Sep; 19(9):e446. PubMed ID: 30122616
[No Abstract] [Full Text] [Related]
12. Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.
Yao Y; Liu J; Li L; Yuan Y; Nan K; Wu X; Zhang Z; Wu Y; Li X; Zhu J; Meng X; Wei L; Chen J; Jiang Z
Oncotarget; 2017 Jan; 8(2):2130-2140. PubMed ID: 27791985
[TBL] [Abstract][Full Text] [Related]
13. [Liquid biopsy : A blood sample for early recognition and therapy control in lung cancer patients].
Hekmat K; Bruns C
Chirurg; 2017 Jul; 88(7):621. PubMed ID: 28616676
[No Abstract] [Full Text] [Related]
14. Updates Regarding Biomarker Testing for Non-Small Cell Lung Cancer: Considerations from the National Lung Cancer Roundtable.
Kim ES; Roy UB; Ersek JL; King J; Smith RA; Martin N; Martins R; Moore A; Silvestri GA; Jett J
J Thorac Oncol; 2019 Mar; 14(3):338-342. PubMed ID: 30709747
[No Abstract] [Full Text] [Related]
15. Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy.
Li L; Wang Y; Shi W; Zhu M; Liu Z; Luo N; Zeng Y; He Y
Cancer Med; 2019 Dec; 8(18):7669-7678. PubMed ID: 31692284
[TBL] [Abstract][Full Text] [Related]
16. [Research progress of circulating tumor DNA methylation in non-small cell lung cancer].
Yang Lan L; Chen Bojiang BJ; Li Lei L
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Dec; 41(12):967-970. PubMed ID: 30522195
[No Abstract] [Full Text] [Related]
17. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
[TBL] [Abstract][Full Text] [Related]
18. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients.
Tran LS; Pham HT; Tran VU; Tran TT; Dang AH; Le DT; Nguyen SL; Nguyen NV; Nguyen TV; Vo BT; Dao HT; Nguyen NH; Tran TH; Nguyen CV; Pham PC; Dang-Mai AT; Dinh-Nguyen TK; Phan VH; Do TT; Truong Dinh K; Do HN; Phan MD; Giang H; Nguyen HN
PLoS One; 2019; 14(12):e0226193. PubMed ID: 31841547
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of Bronchial Washing Fluid-Based Approach to Early-Stage Lung Cancer Diagnosis.
Ryu JS; Lim JH; Lee MK; Lee SJ; Kim HJ; Kim MJ; Park MH; Kim JS; Nam HS; Park N; Yong SJ
Oncologist; 2019 Jul; 24(7):e603-e606. PubMed ID: 31036768
[TBL] [Abstract][Full Text] [Related]
20. Reproducibility of a semiquantitative measurement of circulating DNA in plasma from neoplastic patients.
Frattini M; Balestra D; Verderio P; Gallino G; Leo E; Sozzi G; Pierotti MA; Daidone MG
J Clin Oncol; 2005 May; 23(13):3163-4; author reply 3164-5. PubMed ID: 15860889
[No Abstract] [Full Text] [Related]
[Next] [New Search]
